This company has been marked as potentially delisted and may not be actively trading. Akers Biosciences (AKER) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock AKER vs. MYMD, NAVB, VNRX, SBFM, SLXN, INAB, AIM, EVGN, LUCY, and TCRTShould you be buying Akers Biosciences stock or one of its competitors? The main competitors of Akers Biosciences include MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), VolitionRx (VNRX), Sunshine Biopharma (SBFM), Silexion Therapeutics (SLXN), IN8bio (INAB), AIM ImmunoTech (AIM), Evogene (EVGN), Innovative Eyewear (LUCY), and Alaunos Therapeutics (TCRT). These companies are all part of the "medical" sector. Akers Biosciences vs. Its Competitors MyMD Pharmaceuticals Navidea Biopharmaceuticals VolitionRx Sunshine Biopharma Silexion Therapeutics IN8bio AIM ImmunoTech Evogene Innovative Eyewear Alaunos Therapeutics Akers Biosciences (NASDAQ:AKER) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends. Does the media prefer AKER or MYMD? In the previous week, Akers Biosciences' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score. Company Overall Sentiment Akers Biosciences Neutral MyMD Pharmaceuticals Neutral Do insiders and institutionals hold more shares of AKER or MYMD? 5.5% of Akers Biosciences shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 0.3% of Akers Biosciences shares are held by company insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, AKER or MYMD? Akers Biosciences has higher revenue and earnings than MyMD Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkers Biosciences$1.58M1.00-$3.89MN/AN/AMyMD PharmaceuticalsN/AN/A-$4MN/AN/A Which has more risk & volatility, AKER or MYMD? Akers Biosciences has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500. Is AKER or MYMD more profitable? Akers Biosciences' return on equity of -87.42% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Akers BiosciencesN/A -87.42% -73.31% MyMD Pharmaceuticals N/A -179.05%-108.14% SummaryAkers Biosciences beats MyMD Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Akers Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AKER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKER vs. The Competition Export to ExcelMetricAkers BiosciencesDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.58M$18.09M$5.50B$9.40BDividend YieldN/AN/A3.80%4.05%P/E RatioN/AN/A28.0819.83Price / Sales1.0018.54433.49100.57Price / CashN/AN/A35.8457.94Price / Book0.020.018.135.64Net Income-$3.89M-$15.34M$3.25B$257.88M Akers Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKERAkers BiosciencesN/A$0.09-13.1%N/A-94.3%$1.58M$1.58M0.004Gap DownHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.10-6.3%N/A-94.3%$242KN/A0.006Gap DownHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-90.0%$20K$8.13K0.0010VNRXVolitionRx2.1395 of 5 stars$0.65-4.5%$3.50+435.3%+3.3%$67.99M$1.31M-1.8280News CoverageAnalyst ForecastGap UpSBFMSunshine Biopharma3.2869 of 5 stars$1.51+1.2%$15.00+894.7%+398.3%$6.79M$34.87M-0.013Positive NewsGap DownSLXNSilexion TherapeuticsN/A$0.76-2.4%$5.00+557.8%N/A$6.77MN/A0.00N/ANews CoveragePositive NewsINABIN8bio3.4702 of 5 stars$2.16-2.7%$180.00+8,233.3%-91.5%$6.72MN/A-0.1620AIMAIM ImmunoTech1.4783 of 5 stars$8.79-4.0%$275.00+3,030.0%-79.5%$6.71M$146K-18.6920Gap DownEVGNEvogene2.9068 of 5 stars$1.26+0.8%$3.50+177.8%-78.5%$6.71M$8.51M-0.47140Gap UpLUCYInnovative Eyewear0.3625 of 5 stars$2.16+0.5%N/A-71.3%$6.66M$1.64M-0.549TCRTAlaunos Therapeutics0.6124 of 5 stars$3.38-15.5%N/A-47.4%$6.56M$10K-1.3340News CoveragePositive News Related Companies and Tools Related Companies MyMD Pharmaceuticals Alternatives Navidea Biopharmaceuticals Alternatives VolitionRx Alternatives Sunshine Biopharma Alternatives Silexion Therapeutics Alternatives IN8bio Alternatives AIM ImmunoTech Alternatives Evogene Alternatives Innovative Eyewear Alternatives Alaunos Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKER) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes ...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akers Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akers Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKER Stock Alerts